The FDA-Approved Tanning Peptide: A Clinical Review of Afamelanotide (Scenesse) and the Melanocortin Pathway
An evidence-based review of afamelanotide (Scenesse), the only FDA-approved melanocortin-1 receptor agonist that induces skin pigmentation — its mechanism, approved indication, efficacy and safety data, off-label use for tanning, and the dangerous unregulated melanotan II market dermatologists need to know about.
Afamelanotide (brand name Scenesse, Clinuvel Pharmaceuticals) is the only peptide approved by the U.S. Food and Drug Administration (FDA) to increase skin pigmentation, but its indication is strictly limited to the treatment of erythropoietic protoporphyria (EPP). Approved in October 2019, afamelanotide reduces the risk of phototoxic reactions in adult patients with EPP, a rare genetic disorder characterized by severe pain and skin damage upon light exposure. Despite its clinical utility, public confusion often arises due to the widespread availability of unregulated peptides like melanotan II (MT-II), which are falsely marketed as tanning agents. Unlike afamelanotide, melanotan II is illegal, not FDA-approved, and associated with significant safety concerns. This review aims to clarify the mechanisms, pharmacology, and clinical applications of afamelanotide while distinguishing it from non-approved substances in the melanocortin pathway. Importantly, afamelanotide is not approved for cosmetic tanning purposes. The Melanocortin Pathway: Why a Peptide Can Make Skin Tan The melanocortin pathway is central to the regulation of skin pigmentation, primarily through the action of α-melanocyte-stimulating hormone (α-MSH) on the melanocortin-1 receptor (MC1R), a G-protein-coupled receptor expressed on melanocytes. Upon binding of α-MSH to MC1R, intracellular signaling is initiated via cyclic adenosine monophosphate (cAMP), which activates microphthalmia-associated transcription factor (MITF). MITF is the master regulator of melanogenesis, driving the transcription of enzymes such as tyrosinase that are essential for melanin synthesis. This pathway governs the balance between eumelanin (brown-black pigment) and pheomelanin (red-yellow pigment), favoring eumelanin production under conditions of high MC1R activity. Genetic variants in MC1R significantly influence pigmentation phenotypes. Loss-of-function mutations in MC1R are strongly associated with red hair, fair skin, and i